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Antithrombin Dublin is an electrophoretically fast variant of antithrombin which has normal heparin affinity. Direct sequencing of amplified exon 
2 revealed a Val-*Glu substitution at position -3. N-terminal sequencing of antithrombin from two individuals, heterozygous for the Dublin 
mutation, showed the presence of a truncated antithrombin in which the N-terminal dipeptide is absent. We propose that the prepeptide mutation 
redirects ignal peptidase cleavage to a site two amino acids downstream into the mature protein. 
Antithrombin; N-terminal variant; Truncated serpin 
1. INTRODUCTION 
Human antithrombin is a 58 kDa heparin-activated 
serpin and the major inhibitor of thrombin in plasma 
[ 1,2]. Its physiological importance is emphasised by the 
recurrent thromboses experienced by individuals with a 
deficient or functionally abnormal antithrombin [3]. A 
number of antithrombin variants having defective 
thrombin inhibitory activity and, or altered heparin 
binding have been recognised and been shown to in- 
volve mutations primarily in exons 2 and 6 of the coding 
sequence [4]. 
Antithrombin Dublin was originally studied in four 
Irish families with no history of thrombosis and has 
been the subject of a previous report [5]. It is more 
negatively charged than normal antithrombin and ap- 
pears to have normal heparin affinity. In the course of 
sequencing the antithrombin gene in one antithrombin 
Dublin heterozygote, we found that the DNA encoding 
the signal peptide contained a valine to glutamate 
substitution at position - 3 in the signal peptide. A se- 
cond, unrelated individual, under investigation for 
recurrent thromboses, was found to have the same 
mutation. N-Terminal sequence analysis of the variant 
protein from both individuals indicates the mutation 
gives rise to an aberrant signal peptidase cleavage site 
two amino acids downstream of the normal N-terminal 
histidine occurring after an adjacent glycine. 
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2. MATERIALS AND METHODS 
2.1. Materials 
All reagents, unless otherwise stated, were from Sigma. Deox- 
ynucleotides and T4-polynucleotide kinase were obtained from 
Pharmacia-LKB Biotechnology, Thermus aquaticus (Taq) polymer- 
ase from Perkin Elmer Cetus and low melting point agarose from 
Biorad. Ultrapure urea and agarose were from Gibco-BRL. DNA 
sequencing was performed using Sequenase (Version 2.0, Modified 
T7 DNA Polymerase) from the United States Biochemical Corpora- 
tion. Chromogenic substrate TH was obtained from Boehringer 
Mannheim. 
2.2. Measurement of plasma antithrombin levels 
Antithrombin antigen was measured by competitive ELISA as 
previously described [6]. Antithrombin anti-Ha activity was measured 
in the presence of 60 U/l heparin; chromogenic substrate 
(Chromozym TH) was added after 30 s, and the absorbance change 
at 405 nm recorded [7]. Anti-Xa activity was measured in the presence 
of 1000 U/ml heparin using the substrate S2222 as described by 
Odegaard et al. [8]. Values were expressed as a percentage of a 
reference plasma defined as 100%. 
2.3. Amplification of exon 2 of the antithrombin gene 
Oligonucleotides 5’-CCAGGTGGGCTGGAATCCTCTGCTTT 
and 5 ’ -CCATCAGTTGCTGGAGGGTGTCATTA spanning posi- 
tions 41-507 within segment 2 of the antithrombin sequence [9] were 
synthesized on an Applied Biosystems DNA Synthesizer and used as 
amplification primers without further purification. DNA was 
amplified using the Polymerase Chain Reaction (PCR) as previously 
described 171. Following amplification, the 467 bp DNA fragment was 
purified by electrophoresis n 1% low melting point agarose in TAE. 
The amplified band was excised under UV-light and the DNA ex- 
tracted by subjecting the gel slice to two cycles of freezing and thaw- 
ing [lo]. Following centrifugation in a bench top centrifuge, the 
supernatant was extracted with phenol and chloroform and the DNA 
recovered by ethanol precipitation. The pellet was washed with 70% 
ethanol, dried and resuspended in 9 d HzO. 
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2.4. Direct sequencing of ampfified exon 2 
An oligonucleotide 5’ -CTTGGTCATAGCAAAAGCCG spanning 
positions 451-470 on the non-coding strand of segment 2 of the an- 
tithrombin sequence [9] was synthesised as for the amplification 
primers but purified before use by electrophoresis on a 20% denatur- 
ing polyacrylamide gel and subsequent elution. Sequencing was per- 
formed using a modified Sanger dideoxy sequencing protocol as 
described [ll]. 
2.5. Isolation of ~~tith~om~in and N-terminal protein sequencing 
Antithrombin was isolated from plasma by affinity 
chromato~aphy on heparin Sepharose [12]. The ~tithrombin frac- 
tion was concentrated and dialysed against 20 mM Tris, pH 7.8, and 
then injected onto a Mono Q HR 5/5 anion exchange column (Phar- 
macia) attached to a Waters 650E automated chromatography system 
and equilibrated with 20 mM Tris, pH 7.8. Antithrombin was eluted 
using a linear gradient of 0 to 1 M NaCl in equilibration buffer over 
60 min. 
As a final step, the antithrombin was injected onto a Cl8 reverse 
phase HPLC column (Waters pBondapak) on a Waters HPLC system 
equilibrated with 0.1% TFA in water and eluted with a linear gradient 
to 100% from 0.1 crlo TFA in acetonitrile over 80 min. 
The purified antithrombin, that is, the heterozygous mixture of 
normal and abnormal components, was vacuum dried and N-terminal 
sequencing performed using an Applied Biosystems automated se- 
quencer. 
3. RESULTS 
3.1. Case histories 
Case 1 is a 21-year-old man whose sib was one of the 
original antithrombin Dublin individuals mentioned in 
an earlier report [5]. This individual was well and had 
no history of thrombosis at the time of investigation. 
Case 2 is a 42-year-old man who had a coronary 
thrombosis at age 33 and a spontaneous deep vein 
thrombosis and pulmona~ embolus at age 41. 
3.2. Plasma a~tithrom~in levels 
Plasma antithrombin assays showed both patients 
had low heparin induced inhibitory activity but normal 
antigenic levels (Table I). 
3.3. Amplification and sequencing of exon 2 
Amplification of exon 2 in DNA from both in- 
dividuals generated a single fragment of 467 bp. This 
fragment encodes amino acid residues Lys-18 to Ala-94 
and 77 bp of the 5’ flanking intro& sequence. Sequen- 
cing of the PCR product revealed two nucl~tides at 
position 189 of segment 2 [9] in the codon for amino 
acid -3 of the signal peptide (Pig. 1). Thus, the two 
Table I 
Plasma antithrombin levels 
Antigenic Anti-IIa Anti-Xa 
level (%) activity (qo) activity (olo) 
Normal Range 80-100 75-127 83-l 15 
Case I 110 71 82 
Case 2 103 74 83 
Results are the mean of four determinations. Activity assays were per- 
formed in the presence of heparin. 
88 
Fig. 1. Direct sequencing of the antisense strand of antithrombin 
Dublin. The position of the mutation in codon - 8 is arrowed. The se- 
quence from the bottom of the gel is complementary to the sense 
strand; in the normal gene codon - 3, which codes for Val, is CAC 
(GTG on the sense strand) and in antithrombin Dublin codon - 3 is 
CTC (GAG on the sense strand) which codes for Glu. 
possible codons are GTG, which codes for the expected 
Val, or GAG which codes for Glu. 
3 A. N-Terminal protein sequencing 
In order to examine whether the -3 Val+Glu 
substitution was associated with an alteration in signal 
peptide processing, antithrombin was isolated from the 
plasma of both individuals and subjected to N-terminal 
sequencing for 7 cycles. Two sequences were found in 
both samples: H G S P V D I and S P V D I (C) T A. 
The former corresponds to the expected N-terminal of 
normal antithrombin whilst the latter is identical apart 
from the absence of the N-terming dipeptide, His-Gly. 
This indicated that the -3 Val+Glu substitution has 
resulted in aberrant signal peptide cleavage and produc- 
tion of a truncated form of plasma antithrombin begin- 
ning at position Ser + 3 (Fig. 2). 
-32 -20 -IO .I *I rs 
Normal Antilhrombin MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTC l. HGSPV 
-34 22 -12 -1 +1 +3 
Antithrombin Dublin MYSNVtGTVTSGKRKVYLLSLLLtGfWDCETCHG J SPV 
Fig. 2. Predicted amino acid sequence of antithrombin Dublin. Ar- 
rows indicate the expected and proposed new site of signal peptidase 
cleavage. The position of the muta~on in ~tithrombin Dublin is 
underlined. 
Volume 273, number 1,2 FEBSLETTERS October 1990 
10 
1 
Normal antithrombin 
z Antithrombin Dublin 
0 
$ 
-10 
-202 
-10-9 -8 -7 -6 -5 -4 -3 -2 -1 +I +2 +3 +4 +5 +6 +7 +8 
Position 
Fig. 3. - 13 to + 2 weight matrix scores as a function of the position 
of the moving window. The highest scoring window position is the 
predicted site of signal peptidase cleavage. 
4. DISCUSSION 
The Val-rGlu substitution in the signal peptide and 
the appearance of a truncated antithrombin in plasma 
from the propositi confirms the original description of 
antithrombin Dublin as an inherited variant with both 
individuals studied here being heterozygous for the 
mutation. Antithrombin Dublin is co-eluted with nor- 
mal antithrombin from heparin Sepharose at a NaCl 
concentration of 0.7 M suggesting that the N-terminal 
dipeptide, His-Gly, is not essential for normal heparin 
affinity. The increased net negative charge of an- 
tithrombin Dublin which is observed following isoelec- 
tric focusing and immunoblotting of plasma antithrom- 
bin is explained by the loss of the positively charged N- 
terminal His residue. We propose that the negative 
charge introduced by the - 3 Val-rGlu mutation 
redirects signal peptidase cleavage to a new site located 
two amino acid residues into the mature protein se- 
quence .
Comparisons of aligned amino acid sequences of 
known prepeptides have revealed some regularities and 
clues to the specificity of signal peptidase which have 
been summarised as the ‘ - 3, - 1’ rule [13] or the ‘A- 
X-B’ model [ 141. Thus, amino acids having small 
neutral side chains (i.e. Ala, Gly, Ser, Cys, Thr) 
dominate strongly in positions - 1 and - 3. Certain 
hydrophobic residues (i.e. Leu, Lle, Val) are also 
preferred at position -3 while charged, aromatic and 
large polar residues are absent from both positions. 
These qualitative rules have been incorporated by Von 
Heijne into a method which uses a data base of 161 
aligned eukaryotic signal sequences and a standard 
weight matrix approach to predict the site of signal pep- 
tidase cleavage [ 151. To locate the most probable 
cleavage site in antithrombin Dublin, - 13 to + 2 
weight matrices were constructed for the normal and 
mutated signals using the amino acid counts matrix and 
the method described by Von Heijne in [IS]. The scores 
obtained by summing the contributions from - 13 to 
+2 were examined as a function of the position of a 
moving window, the highest scoring window position 
being the predicted site of cleavage. As expected, the 
highest score with the normal antithrombin signal was 
obtained for position - 1 (i.e. between Cys - 1 and His 
+ 1; Score = 8.18 (Fig. 3). With the mutated signal of 
antithrombin Dublin, the score for position - 1 was 
much smaller than that obtained for the normal se- 
quence, indicating the reduced probability of normal 
signal peptidase cleavage. The highest scores were ob- 
tained for positions - 2 (i.e. Thr - 2lCys - 1; Score = 
4.51) and + 2 (i.e. Gly + 2lSer + 3; Score = 4.29). This 
indicates that the Val-+Glu mutation in antithrombin 
Dublin generates two alternative sites of signal pep- 
tidase cleavage located between Gly- 2 and Ser - 3, 
where cleavage occurs, and also between Thr - 2 and 
Cys - 1. A relevant analogous example is that of 
albumin Redhill [16], where, similarly, a prepeptide 
mutation generates two possible sites of signal pep- 
tidase cleavage. Since an extended antithrombin having 
an N-terminal Cys residue was not detected in plasma 
from the propositi, we suggest that, in contrast to the 
case of albumin Redhill [16] Ser is more favoured than 
Cys in directing signal peptidase cleavage. 
The clinical importance of antithrombin Dublin re- 
mains unclear. Characterisation of further variants 
with the identical mutation should clarify the natural 
history of this variant. 
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